Latest Research And Development News

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

AML3D Limited reported steady quarterly receipts alongside a landmark US Navy Letter of Intent and significant orders, underpinning a major growth phase in the US and Europe.

Phoslock Environmental Technologies reported a $952,000 operating cashflow deficit in Q3 2025 amid rising legal and logistics expenses, while sales volumes improved and production is set to resume in early 2026.

International Graphite Limited has taken significant steps toward establishing Australia’s first commercial graphite micronising plant with land acquisition and key development approvals in Collie, WA.

Diatreme Resources reports significant improvements in mineral recoveries from metallurgical testwork on its Cyclone zircon-rich heavy mineral sands project, enhancing prospects for project development and shareholder value.

ReNerve Limited reported a 38% increase in quarterly sales driven by the launch of its EmpliQ product range and ongoing development of advanced nerve repair technologies. The company’s cash position remains solid as it prepares for upcoming clinical trials.

Audeara Ltd has reported a remarkable 111% revenue increase in Q1 FY26, driven by strong growth in its technology division and key international partnerships in China and Japan. The company is advancing towards cashflow breakeven with improved cash management and expanding global reach.

Cochlear Limited reports steady FY25 financials alongside the launch of its innovative Nucleus Nexa cochlear implant system, setting the stage for projected double-digit profit growth in FY26.

Deep Yellow Limited reported a $10.6 million operating cash outflow for the September quarter but maintains a robust cash position with over $203 million on hand, supporting an estimated 14 quarters of funding.

Beetaloo Energy Australia Limited reported a robust cash position and secured new financing facilities to support ongoing development at its Carpentaria project. Despite significant exploration outflows, the company maintains sufficient liquidity to advance operations.

Weebit Nano has reported a record quarter with A$7.3 million in customer receipts, securing three key product agreements and progressing critical technology milestones at leading semiconductor fabs.

Nyrada has completed its Phase I trial for Xolatryp, confirming safety and predictable pharmacokinetics, while securing AU$8.25 million to fund an upcoming Phase IIa trial targeting heart attack patients.